Isomorphic Labs, a drug design company, secured $600 million in its first external funding round. Thrive Capital led the investment, with contributions from GV and Alphabet. Launched in 2021 with Google DeepMind, Isomorphic unveiled AlphaFold 3, an AI model developed to predict the structure and interactions of proteins, DNA, RNA, and ligands. The company has also developed an AI drug design engine that spans multiple therapeutic areas and drug modalities. The funds will support the advancement of their drug design programs and aim to deliver biomedical breakthroughs. In February, Isomorphic expanded its collaboration with Novartis, adding up to three new research programs. Last year, they partnered with Eli Lilly, receiving a $45 million upfront payment to discover small molecule therapeutics. Google DeepMind introduced AlphaProteo, an AI system trained on the Protein Data Bank to design high-strength proteins.
Demis Hassabis
@demishassabis
·
Mar 31 Thrilled to announce
@IsomorphicLabs
has raised $600M to turbocharge our mission to one day solve all disease with the help of AI.
I’ve long felt that improving human health is the most important thing we can do with AI & today marks a big step towards a new era of drug
Steve Woodward
@WoodyNemo
·
48m Alphabet’s AI drug discovery platform Isomorphic Labs raises $600M from Thrive #ai #IsomorphicLabs https://tinyurl.com/289gqr27
✧Bob Hutchins✧
@BobHutchins
·
1m Google’s AI pharma spin-off Isomorphic Labs raised a massive $600M round to fuel its drug discovery platform
http://reuters.com. The funding, backed by Alphabet and Thrive Capital, underscores investor confidence in #AI for biotech innovation. #DrugDiscovery #AI
Nemo Resourcing
@NemoResourcing
·
48m Alphabet’s AI drug discovery platform Isomorphic Labs raises $600M from Thrive #ai #IsomorphicLabs https://tinyurl.com/289gqr27
Andrew Curran
@AndrewCurran_
·
Jan 21 Sir Demis is speaking in Davos. He expects clinical trials for AI-designed drugs to begin this year. He said Isomorphic Labs, which he founded in 2021, is working on shortening the drug discovery process from a decade or more to ‘weeks or months.’
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
